Moleculin Biotech to Meet With EMA

Moleculin Biotech said Tuesday it will meet with the European Medicines Agency (EMA) Aug. 30 to discuss clinical trial authorization for the study of annamycin for the treatment of acute myeloid leukemia.

With the company’s planned clinical trial for Annamycin in the U.S. and Poland, which may begin soon, dependent upon the filing and allowance of it as an investigational new drug with the U.S. Food and Drug Administration, said CEO Walter Klemp, “we want to be in a position to move quickly with Annamycin in the rest of Europe. This meeting will lay the groundwork for expanding Annamycin’s market throughout the European Union.”

Leave a Comment